AG
ADVM

Aperio Group’s Adverum Biotechnologies ADVM Stock Holding History

Aperio Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$171K Buy
1,578
+317
+25% +$39.2K ﹤0.01% 2332
2020
Q3 		$130K Buy
1,261
+41
+3% +$6.14K ﹤0.01% 2295
2020
Q2 		$255K Buy
+1,220
New +$216K ﹤0.01% 2083
2019
Q3 		– Sell
-126
Closed -$15K – 2310
2019
Q2 		$15K Buy
+126
New +$10.4K ﹤0.01% 2726

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Aperio Group's ADVM Position: Q4 2020 in Review

Aperio Group increased its Adverum Biotechnologies (ADVM) stake by 25% in Q4 2020, buying an estimated $39.2K and bringing the position to 1,578 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

Aperio Group first reported a position in ADVM in Q2 2019 and has held it in 4 quarters since. The position peaked at $255K in Q2 2020. 155 funds tracked by Wall St. Rank hold ADVM as of Q4 2020.

  • Aperio Group held 1,578 shares of Adverum Biotechnologies worth $171K as of Q4 2020.
  • Aperio Group bought 317 Adverum Biotechnologies shares in Q4 2020, an estimated $39.2K.
  • Adverum Biotechnologies made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2332 holding.
  • Aperio Group first reported a position in Adverum Biotechnologies in Q2 2019 and has held it in 4 quarters since.
  • Aperio Group's Adverum Biotechnologies position peaked at $255K in Q2 2020.
  • 155 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.